BRAF and melanoma: Even though included patients were treated in the adjuvant setting for melanoma, patient populations slightly differ since the studied treatments are applied for specific indications within adjuvant treatment (e.g., D + T for BRAF positive patients only, and nivolumab also for resected stage IV).